Edition:
United States

Uniqure NV (QURE.OQ)

QURE.OQ on NASDAQ Stock Exchange Global Select Market

27.73USD
12:10pm EST
Change (% chg)

$0.82 (+3.05%)
Prev Close
$26.91
Open
$26.91
Day's High
$28.40
Day's Low
$26.91
Volume
25,960
Avg. Vol
104,472
52-wk High
$43.23
52-wk Low
$16.73

Latest Key Developments (Source: Significant Developments)

Uniqure announces long-term clinical data from ongoing phase I/Ii trial of AMT-060
Monday, 3 Dec 2018 07:00am EST 

Dec 3 (Reuters) - Uniqure NV ::UNIQURE ANNOUNCES LONG-TERM CLINICAL DATA FROM ONGOING PHASE I/II TRIAL OF AMT-060 AND CONFIRMS DOSE FOR AMT-061 PIVOTAL STUDY IN HEMOPHILIA B.UNIQURE NV - DOSE CONFIRMED FOR PHASE III PIVOTAL STUDY OF AMT-061, WITH PATIENT DOSING EXPECTED TO COMMENCE IN Q1 OF 2019.UNIQURE NV - AMT-060 CONTINUES TO BE SAFE AND WELL-TOLERATED, WITH NO NEW SERIOUS ADVERSE EVENTS AND NO DEVELOPMENT OF INHIBITORS.  Full Article

Uniqure Announces Initial Topline Data From Dose-Confirmation Study Of AMT-061 In Patients With Hemophilia B
Thursday, 15 Nov 2018 08:21am EST 

Nov 15 (Reuters) - Uniqure NV ::UNIQURE ANNOUNCES INITIAL TOPLINE DATA FROM DOSE-CONFIRMATION STUDY OF AMT-061 IN PATIENTS WITH HEMOPHILIA B.UNIQURE - IN STUDY, ALL PATIENTS ACHIEVED THERAPEUTIC FACTOR IX ACTIVITY WITH MEAN FIX LEVEL OF 31% OF NORMAL AT 6 WEEKS AFTER ADMINISTRATION.UNIQURE - AMT-061 HAS BEEN WELL-TOLERATED.UNIQURE - EXPECTS TO SUBMIT DATA FROM PHASE IIB DOSE-CONFIRMATION STUDY OF AMT-061 TO FDA & EMA BY END OF THE YEAR.UNIQURE - EXPECTS TO INITIATE DOSING PHASE OF ITS PHASE III HOPE-B PIVOTAL STUDY IN Q1 2019.  Full Article

Uniqure Announces Third Quarter 2018 Financial Results
Tuesday, 6 Nov 2018 07:00am EST 

Nov 6 (Reuters) - Uniqure NV ::UNIQURE ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS COMPANY PROGRESS.Q3 LOSS PER SHARE $0.59.Q3 REVENUE $3.1 MILLION VERSUS I/B/E/S VIEW $2.8 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.62 -- THOMSON REUTERS I/B/E/S.CURRENTLY EXPECTS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS INTO 2021.  Full Article

uniQure Q3 Loss Per Share $0.59
Tuesday, 6 Nov 2018 07:00am EST 

Nov 6 (Reuters) - Uniqure NV ::UNIQURE ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS COMPANY PROGRESS.Q3 LOSS PER SHARE $0.59.Q3 REVENUE $3.1 MILLION VERSUS I/B/E/S VIEW $2.8 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.62 -- THOMSON REUTERS I/B/E/S.  Full Article

uniQure NV Quarterly Loss Per Share $0.59
Tuesday, 6 Nov 2018 06:28am EST 

Nov 6 (Reuters) - Uniqure NV ::UNIQURE NV QUARTERLY LOSS PER SHARE $0.59.UNIQURE NV QUARTERLY TOTAL REVENUES $3.1 MILLION VERSUS $2.3 MILLION.  Full Article

UniQure ‍on Track To Begin Pivotal Study Of AMT-061 In Hemophilia B In Q3
Wednesday, 14 Mar 2018 07:00am EDT 

March 14 (Reuters) - Uniqure Nv ::UNIQURE ANNOUNCES 2017 FINANCIAL RESULTS AND RECENT COMPANY PROGRESS.UNIQURE NV - ‍ON TRACK TO BEGIN PIVOTAL STUDY OF AMT-061 IN HEMOPHILIA B IN Q3 2018​.UNIQURE NV - ‍EXPECTS IND SUBMISSION FOR AMT-130 IN HUNTINGTON'S DISEASE IN SECOND HALF OF 2018​.UNIQURE NV - ‍$159 MILLION OF CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2017​.  Full Article

Uniqure Says As Of Dec 31 Co Had $159 Mln In Cash & Cash Equivalents
Monday, 8 Jan 2018 07:00am EST 

Jan 8 (Reuters) - Uniqure Nv ::UNIQURE PROVIDES YEAR-END 2017 CORPORATE UPDATE AND OUTLINES NEAR-TERM OBJECTIVES TO FURTHER DRIVE SHAREHOLDER VALUE.UNIQURE - AS OF DEC 31, 2017, CO HAD ABOUT $159 MILLION IN CASH & CASH EQUIVALENTS; EXPECTS CASH ON HAND SUFFICIENT TO FUND OPERATIONS INTO 2020.UNIQURE NV - INTENDS TO INITIATE GLOBAL, PIVOTAL PROGRAM FOR AMT-061 IN HEMOPHILIA B DURING Q3 2018.UNIQURE NV - AMENDMENT TO EXISTING INVESTIGATIONAL NEW DRUG (IND) APPLICATION EXPECTED FOR AMT-061 TO BE SUBMITTED TO FDA IN Q1 2018.  Full Article

UniQure Announces Updated, Long-Term Clinical Data From Ongoing Phase I/II Trial Of AMT-060 In Patients With Severe Hemophilia B
Monday, 11 Dec 2017 07:00am EST 

Dec 11 (Reuters) - Uniqure Nv ::UNIQURE ANNOUNCES UPDATED, LONG-TERM CLINICAL DATA FROM ONGOING PHASE I/II TRIAL OF AMT-060 IN PATIENTS WITH SEVERE HEMOPHILIA B.UNIQURE -AAV5-BASED AMT-060 REMAINS SAFE,WELL-TOLERATED WITH UPTO 2 YEARS OF FOLLOW-UP,WITH NO NEW SERIOUS ADVERSE EVENTS,NO DEVELOPMENT OF INHIBITORS.  Full Article

Uniqure Q3 loss per share $0.40
Wednesday, 1 Nov 2017 07:00am EDT 

Nov 1 (Reuters) - Uniqure Nv ::Uniqure announces third quarter 2017 financial results and recent company progress.Q3 loss per share $0.40.Q3 revenue $2.3 million versus $7.2 million.Q3 revenue view $6.3 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S.  Full Article

UniQure reports Q3 loss $0.40/shr
Wednesday, 1 Nov 2017 07:00am EDT 

Nov 1 (Reuters) - UniQure Nv :UniQure announces third quarter 2017 financial results and recent company progress.Q3 loss per share $0.40.Q3 revenue $2.3 million versus $7.2 million.Q3 revenue view $6.3 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S.  Full Article